{"entity":{"id":"nucleai","kind":"company","name":"Nucleai","aka":[],"tldr":"Nucleai uses artificial intelligence to map where different cells sit within tumour tissue samples, helping drug companies understand who responds to a treatment and why.","summary":"Nucleai, headquartered in Tel Aviv, provides an AI-powered spatial tissue analysis platform for oncology drug development. It integrates multimodal tissue imaging (H&E, immunohistochemistry, multiplex immunofluorescence and spatial transcriptomics) with clinical outcome data to derive explainable spatial biomarkers. The company reports work with more than 12 of the top 20 biopharma companies across 30 or more clinical trials, and holds ISO 27001 and ISO 13485 certification. Recent collaborations include a large-scale antibody-drug conjugate (ADC) programme with Gilead Sciences examining why target-positive tumours resist ADCs (2026), an integrated spatial proteomics offering with Sirona Dx and an expanded partnership with the University of Glasgow. Investors named on the website include Section32, Sanofi, M Ventures and Debiopharm; no financing round is disclosed.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://nucleai.ai/"},{"label":"News page","url":"https://nucleai.ai/news"},{"label":"Gilead ADC collaboration (Aug 2026)","url":"https://nucleai.ai/nucleai-advances-ai-powered-tissue-intelligence-through-large-scale-oncology-adc-collaboration/"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation","drug-discovery"],"technologies":["digital-pathology-ai","single-cell-spatial"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["nucleai.com is now a parked domain; the live site is nucleai.ai. Funding rounds (including a reported 2022 Series B) could not be sourced from primary releases so none are recorded. Founding year not sourced."],"hq":"Tel Aviv","country":"IL","companyType":"ai-software","website":"https://nucleai.ai/","stage":"startup","investors":["section-32","sanofi-ventures"],"funding":[]},"route":"/companies/nucleai/","neighbours":{"section":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/"},{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"}],"technology":[{"id":"digital-pathology-ai","kind":"technology","name":"Digital pathology & AI","route":"/technologies/digital-pathology-ai/"},{"id":"single-cell-spatial","kind":"technology","name":"Single-cell & spatial profiling","route":"/technologies/single-cell-spatial/"}],"company":[{"id":"sanofi-ventures","kind":"company","name":"Sanofi Ventures","route":"/companies/sanofi-ventures/"},{"id":"section-32","kind":"company","name":"Section 32 (S32)","route":"/companies/section-32/"}]}}